

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

In re Application of : FLEENOR et al.
Serial Number : 10/510,585
Filed : October 8, 2004
Examiner : Davis, Ruth A.
Group Art Unit : 1651
Confirmation No : 1893
For: : Agents Which Regulate, Inhibit, or Modulate The Activity and/or Expression of Connective Tissue Growth Factor (CTGF) as a Unique Means to Both Lower Intraocular Pressure and Treat Glaucomatous Retinopathies/Optic Neuropathies

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT
WITH TRAVERSE**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action/Restriction Requirement dated December 5, 2006, for which the one-month date for response is January 5, 2007, please amend the above-identified U. S. patent application as follows:

Amendments to the Claims are shown in a listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.